Clinical Outcomes of Persistent Smoking in Patients with Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention.
- Author:
Soo Young SEOL
1
;
Sook Ja LEE
;
Myung Ho JEONG
;
Jung Ae RHEE
;
Jin Su CHOI
;
Seung Hwan HWANG
;
Jum Suk KO
;
Min Goo LEE
;
Doo Sun SIM
;
Keun Ho PARK
;
Nam Sik YOON
;
Hyun Ju YOON
;
Kye Hun KIM
;
Young Joon HONG
;
Ju Han KIM
;
Youngkeun AHN
;
Jeong Gwan CHO
;
Jong Chun PARK
;
Jung Chaee KANG
Author Information
1. The Heart Center of Chonnam National University Hospital, Gwangju, Korea. myungho@chollian.net
- Publication Type:Original Article
- Keywords:
Myocardial infarction;
Smoking;
Prognosis
- MeSH:
Follow-Up Studies;
Humans;
Male;
Myocardial Infarction;
Percutaneous Coronary Intervention;
Prognosis;
Risk Factors;
Smoke;
Smoking
- From:Korean Journal of Medicine
2011;80(5):562-570
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: To analyze the clinical effects of continuing to smoke in patients with acute myocardial infarction (AMI), clinical outcomes of those continuing or ceasing smoking were compared. METHODS: In total, 498 patients with AMI who underwent percutaneous coronary intervention (PCI) from January to December 2007 were enrolled. Of these patients, 407 (63.9 +/- 11.9 years, males 70%) with 1-year follow-ups were analyzed. Based on risk factors for smoking, patients were divided into two groups: Group I (smokers, n = 164, 57.9 +/- 11.2 years) and Group II (nonsmokers, n = 243, 68.0 +/- 10.6 years). Additionally, Group I patients were subdivided by cessation of smoking after discharge: Group IA (current smokers, n = 95, 56.8 +/- 10.5 years) and IB (past smokers, n = 69, 59.4 +/- 12.0 years). Clinical characteristics, coronary angiographic and procedural findings, and 1year major adverse cardiac events (MACE) were analyzed. RESULTS: During the 1-year follow-up period, MACE developed in 112 patients (27.6%) and death in 42 patients (10.3%). In terms of smoking habits at admission, there was no significant difference in the 1-year MACE between current smokers (Group I) and nonsmokers (Group II). In the subgroup analysis, there were no significant difference in clinical characteristics between Groups IA and IB. Mortality was significantly higher in Group IA than in Group IB during the 1-year clinical follow-up (11% vs. 0%; p = 0.005). CONCLUSIONS: Of the AMI patients who underwent PCI, mortality was significantly higher in current smokers than in past smokers after PCI.
